Why Buccal Troches Can Have Higher Bioavailability Than Pills or Capsules

Buccal troches are small, medicated lozenges that dissolve in the mouth. They are usually held against the inner cheek (the buccal mucosa). Unlike an ordinary pill that you swallow, a troche melts in the cheek, releasing the drug or compound directly into the tissues there. This simple change of delivery method can permit a lot more of the drug to reach the bloodstream in its active form. In other words, buccal (cheek) administration often gives higher bioavailability than a swallowed pill. In this article, we’ll explain what that means and why it matters.

How Buccal Troches Work

Buccal absorption is the process by which a drug is absorbed through the tissues of the cheek, directly into the blood. The inside of the mouth (i.e., the oral mucosa) has a thin lining and lots of tiny blood vessels just beneath the surface. When a troche dissolves there, the drug diffuses across the mucous membrane and is picked up by the capillaries (small blood vessels) under the cheek. It then enters the veins that drain into the main circulation, bypassing the gastrointestinal (GI) tract and the liver’s first-pass effect. In other words, buccal absorption lets the drug go straight into systemic circulation, much like an injection (though of course no needle is used).

The buccal mucosa is especially well suited for rapid absorption. It has a thin, moist surface and rich blood supply, so medications can enter the blood efficiently. By contrast, a swallowed tablet must first survive stomach acid and various enzymes in the gut, which can destroy or alter some drugs before absorption. A buccal troche typically dissolves slowly over several minutes in the cheek. During that time, its active ingredients are steadily absorbed through the mucosa and into the bloodstream.

What is Bioavailability and First-Pass Metabolism?

To compare buccal troches versus oral pills, it helps to understand bioavailability and first-pass metabolism in their simplest terms. Bioavailability is the fraction of a drug dose that ends up in the bloodstream ready to exert its effects. By definition, 100% bioavailability means the entire dose reaches circulation; most oral drugs have less than 100% bioavailability. The rest of the drug can be lost (for example, it might never dissolve fully, or it could be metabolized first).

When you swallow a drug, it must be absorbed through the gastrointestinal (GI) tract and then travel to the liver before it can reach the rest of the body. The liver and intestinal wall enzymes often break down a sizable chunk of the dose in this first pass. That’s why the "oral bioavailability" of some drugs can be quite low. For instance, morphine is heavily metabolized in the liver, so only a fraction of a swallowed morphine dose remains active. Hence, oral doses of morphine have to be much larger than if it were administered by injection.

In contrast, IV injections deliver 100% of the drug to the bloodstream immediately, precisely because they skip all absorption steps. Sublingual or buccal routes are not quite as direct as IV, but they share the key advantage of largely avoiding first-pass metabolism. A drug absorbed through the cheek or under the tongue goes straight into the veins that connect to the heart, bypassing the liver until after it has circulated through the body [1,2].

Buccal vs. Oral Administration: Two Pathways of Absorption

We can summarize these two pathways in distinct steps.

When you swallow a pill or capsule, it travels to the stomach and intestines. The pill must dissolve in the fluids of the GI tract, and its drug molecules pass through the intestinal lining into the portal bloodstream, which immediately carries them to the liver. In the liver, enzymes (especially the cytochrome P450 system) chemically modify many drugs, breaking them down to inactive forms. Only then does the remaining active drug enter the general circulation. Along this pathway, a lot of the compound can be lost due to stomach acid, gut enzymes, or liver metabolism.

Conversely, a troche is placed in the cheek, usually between the gum and inner cheek tissue. It dissolves slowly in saliva, and the drug then diffuses across the cheek’s mucous membrane directly into tiny blood vessels. From there, it enters the venous system (often the jugular veins) and travels to the heart, enabling distribution throughout the body. Crucially, it skips the gut and liver on the first pass. Only later, after the drug has circulated, will it eventually reach the liver in the normal way (i.e., as part of circulation outflow). Because the initial route avoids the intensive GI/liver metabolism, a much larger fraction of the original dose remains active in the body.

Each step where the drug can be degraded or delayed is shorter or eliminated via the buccal route. The oral mucosa itself has a thin epithelium and is highly vascular, which favors absorption.

Practical Implications of Buccal Troches: Dosing, Effectiveness, and Onset

Higher bioavailability through buccal administration has several practical effects.

Since a buccal troche largely avoids first-pass breakdown, a greater fraction of the original dose enters the bloodstream as active drug. For example, a drug with 30% bioavailability when swallowed might have a significantly higher percentage buccally. This means the medication can be more potent or efficient per milligram provided. In practice, doctors can often use smaller doses with buccal dosing to achieve the same effect. As noted earlier, drugs subject to heavy first-pass metabolism require much higher oral doses, whereas buccal forms sidestep that necessity.

Given that more of the dose is making its way into the circulation, you may not need to take as much medication. This can reduce pill burden and cost, offering a substantial degree of convenience. It can also lessen side effects caused by very high doses. For example, nitroglycerin tablets for chest pain have a better effect at smaller doses when taken sublingually (under the tongue) compared to swallowing [3-5]. This is why emergency angina drugs are given as fast-dissolving troches or sprays under the tongue.

When drugs arrive directly into the blood, they can start working faster. For many buccal or sublingual drugs, relief is felt within minutes rather than an hour or more. Sublingual nitroglycerin can quickly relieve angina symptoms because it bypasses first-pass metabolism. Similarly, buccal troches can begin acting faster than pills. The increased vascular contact and circumvention of GI transit mean the drug appears in the blood and reaches its target sites more rapidly.

Two randomized clinical trials were conducted to evaluate the efficacy of buccal acetaminophen for pain relief in healthy volunteers compared to sublingual and intravenous routes [6]. Buccal administration of acetaminophen provided faster analgesia, with an onset of pain relief within just 15 minutes, compared to other routes. As such, buccal administration could be a better alternative to other routes of administration as it produces a faster onset of action.

Swallowed pills must also survive stomach acid and digestive enzyme exposure [7]. Some drugs are sensitive to these conditions. For instance, insulin or certain hormones would be completely destroyed by stomach acid if swallowed. Using a buccal troche means the drug never touches the stomach before absorption [8-10].

Oral absorption can be highly variable. Factors like food intake, stomach pH, gut motility, and individual liver enzyme differences all affect how much drug gets through. Buccal absorption tends to be more reliable in that sense, because the factors in the mouth are more constant. The oral mucosa has a relatively neutral pH and fewer digestive enzymes, so absorption is steadier. Also, since the drug isn’t racing through the gut, the absorption rate is often more controlled (especially if the troche dissolves slowly).

Lastly, for some people, swallowing pills is difficult (e.g., children, the elderly, or those with esophageal problems). Buccal troches can be an easier alternative that offers speed and convenience. They are especially useful when you need a non-invasive but fast-acting route (e.g., pain relief, hormonal therapy). While this does not directly concern bioavailability, it affects treatment effectiveness in practice.

Buccal Troches at Troscriptions

At Troscriptions, the use of buccal troches is a purposeful design decision rather than a novelty in supplement delivery.

Each troche is developed by physicians and formulated specifically for transmucosal absorption through the cheek lining. By using the buccal route, these formulations are designed to work with the body’s natural pharmacokinetics — allowing compounds to be absorbed directly through the oral mucosa rather than relying entirely on gastrointestinal digestion and first-pass liver metabolism. This delivery approach can support more predictable systemic uptake for compounds that benefit from rapid or efficient absorption.

Troscriptions troches are also precision-dosed and scored, making it possible to divide each troche into smaller portions for gradual titration. This flexibility allows individuals to identify the lowest effective dose instead of relying on a fixed, one-size-fits-all serving.

Formulation quality is another central focus. Troscriptions uses pharmaceutical-grade manufacturing practices and carefully verified ingredients to ensure consistency from batch to batch. The goal is not simply to create a dissolvable tablet, but to engineer a delivery format that maintains close contact with the buccal mucosa and supports reliable absorption.

When properly designed and used, buccal troches represent a practical application of anatomy, pharmacology, and formulation science. By combining thoughtful compound selection with a delivery system optimized for transmucosal uptake, Troscriptions aims to provide compounds in a format that is both efficient and easy to individualize.

Conclusion

In summary, because buccal troches deposit the drug in the cheek lining and therefore avoid the GI tract and first-pass metabolism, more of each dose reaches the systemic circulation in its active form. This can permit smaller doses, faster pain or symptom relief, and potentially fewer side effects. Drug manufacturers and compounding pharmacies exploit this for certain medications (such as hormones, antivirals, and some pain and nausea medications) to improve efficacy.

It’s important to note that not all drugs are suited to buccal delivery. The drug must be able to penetrate the cheek lining. When this is a possibility, the improvement in bioavailability can be striking. Higher bioavailability means you get the intended therapeutic effect more efficiently. For patients and prescribers, this translates into more effective dosing strategies and a potentially quicker onset of relief, thanks to the pharmacokinetic advantages of the buccal route.

References

[1]         R. Sabra, D. Kirby, V. Chouk, K. Malgorzata, A.R. Mohammed, Buccal Absorption of Biopharmaceutics Classification System III Drugs: Formulation Approaches and Mechanistic Insights, Pharmaceutics 16 (2024) 1563. https://doi.org/10.3390/pharmaceutics16121563.

[2]         H. Zhang, J. Zhang, J.B. Streisand, Oral Mucosal Drug Delivery: Clinical Pharmacokinetics and Therapeutic Applications, Clinical Pharmacokinetics 41 (2002) 661–680. https://doi.org/10.2165/00003088-200241090-00003.

[3]         W.E. Boden, S.K. Padala, K.P. Cabral, I.R. Buschmann, M.S. Sidhu, Role of short-acting nitroglycerin in the management of ischemic heart disease, Drug Des Devel Ther 9 (2015) 4793–4805. https://doi.org/10.2147/DDDT.S79116.

[4]         H. Sato, Y. Koretsune, T. Taniguchi, S. Fukui, T. Shimazu, M. Sugii, T. Matsuyama, M. Karita, M. Hori, Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial, Arzneimittelforschung 47 (1997) 128–131.

[5]         M.J. Twiner, J. Hennessy, R. Wein, P.D. Levy, Nitroglycerin Use in the Emergency Department: Current Perspectives, Open Access Emerg Med 14 (2022) 327–333. https://doi.org/10.2147/OAEM.S340513.

[6]         G. Pickering, N. Macian, F. Libert, J.-M. Cardot, S. Coissard, P. Perovitch, M. Maury, C. Dubrey, Buccal acetaminophen provides fast analgesia: two randomized clinical trials in healthy volunteers, DDDT (2014) 1621. https://doi.org/10.2147/DDDT.S63476.

[7]         S. Hua, Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration, Front. Pharmacol. 10 (2019) 1328. https://doi.org/10.3389/fphar.2019.01328.

[8]         V.R. Solanki, V.K. Parmar, Recent Advances in Development of Buccal Formulations: From Small to Macromolecules, AAPS PharmSciTech 26 (2025) 156. https://doi.org/10.1208/s12249-025-03154-z.

[9]         A. Ahmad, J. Akhtar, M. Ahmad, R. Wasim, M.I. Khan, Drug Delivery Approaches for Buccal and Sublingual Administration, Drug Res (Stuttg) 75 (2025) 239–250. https://doi.org/10.1055/a-2560-9884.

[10]       S. Bahraminejad, H. Almoazen, Sublingual and Buccal Delivery: A Historical and Scientific Prescriptive, Pharmaceutics 17 (2025) 1073. https://doi.org/10.3390/pharmaceutics17081073.